Overview
The ketogenic diet restricts carbohydrates to 20-50 g/day (or <10% of calories), forcing a metabolic shift from glucose oxidation to fatty acid beta-oxidation and hepatic ketogenesis. The resulting ketone bodies — beta-hydroxybutyrate (BHB), acetoacetate, and acetone — serve as alternative fuel and as signaling molecules with distinct anti-inflammatory and epigenetic effects.
> Clinical disclaimer: The ketogenic diet requires medical supervision, especially in patients on diabetes medications (hypoglycemia risk), anticonvulsants (dose adjustments needed), or with kidney disease. Nutritional adequacy must be monitored. Not appropriate for patients with fatty acid oxidation disorders, porphyria, or pyruvate carboxylase deficiency.
—-
Mechanism of Action
The ketogenic diet operates through metabolic reprogramming with downstream effects on inflammation, gene expression, and the microbiome:
- BHB as HDAC inhibitor: Beta-hydroxybutyrate directly inhibits Class I and IIa histone deacetylases, promoting expression of anti-oxidant genes (FOXO3a, SOD2, catalase) and neurotrophic factors (BDNF). This epigenetic mechanism distinguishes the ketogenic diet from simple caloric restriction.
- Insulin reduction: Carbohydrate restriction profoundly lowers circulating insulin — the most direct dietary manipulation of insulin signaling. Relevant for pcos, type 2 diabetes, and insulin-driven cancer metabolism.
- Microbiome remodeling: The ketogenic diet produces a distinctive microbiome shift — increased Akkermansia muciniphila and Parabacteroides merdae, which cross-feed to elevate hippocampal GABA/glutamate ratio. In MS, Swidsinski showed normalized colonic bacterial mass, suggesting architectural rather than just compositional changes.
- Mitochondrial bypass: Ketones enter the electron transport chain at complex II, bypassing the complex I defect central to parkinsons disease and other mitochondrial disorders.
- Anti-inflammatory signaling: BHB blocks NLRP3 inflammasome activation and reduces IL-1-beta, TNF-alpha, and IL-6 production.
—-
Dosage and Administration
| Parameter | Standard Protocol | Notes |
|---|---|---|
| Carbohydrate | 20-50 g/day (5-10% calories) | Strict <20 g for epilepsy; 30-50 g tolerated for other conditions |
| Fat | 70-80% of calories | Emphasize EVOO, avocado, fatty fish, nuts; limit saturated fat |
| Protein | 15-20% of calories | Moderate — excess protein converts to glucose via gluconeogenesis |
| Induction period | 2-4 weeks to achieve stable ketosis | "Keto flu" (fatigue, headache) common during adaptation |
| Duration | Condition-dependent: 3-6 months minimum for assessment | Epilepsy: often long-term. PCOS/MS: 3-6 month trial |
| Modified versions | MCT ketogenic, modified Atkins, low glycemic index treatment | Lower fat ratio improves adherence with similar ketosis in some patients |
—-
Monitoring
- Blood ketone levels (BHB): Target 0.5-3.0 mmol/L for nutritional ketosis. Urine ketone strips are unreliable after adaptation. Blood BHB meters preferred.
- Lipid panel: At baseline, 3 months, 6 months. LDL may transiently rise; monitor LDL particle size (large buoyant = less concerning than small dense).
- Renal function: BUN/creatinine at baseline and 3 months. Adequate hydration essential.
- Electrolytes: Sodium, potassium, magnesium — ketosis increases urinary electrolyte loss. Supplementation often needed (sodium 3-5g, potassium 1-3g, magnesium 300-500mg daily).
- Bone density: Long-term pediatric KD associated with reduced bone mineral density. Monitor in children and postmenopausal women.
—-
Contraindications and Risks
- Fatty acid oxidation disorders: Absolute contraindication — inability to utilize fat for energy makes KD lethal.
- Porphyria, pyruvate carboxylase deficiency: Absolute contraindications.
- Kidney stones: 3-7% incidence in long-term KD (especially pediatric). Potassium citrate prophylaxis recommended.
- Hypoglycemia: Patients on insulin or sulfonylureas require medication dose reduction BEFORE starting KD.
- Nutrient deficiencies: Fiber, B vitamins, vitamin C, and minerals may be insufficient without careful planning. Micronutrient supplementation recommended.
- Adherence: 30-50% dropout rate in clinical trials. Social and practical difficulties limit long-term sustainability.
- LDL cholesterol: Lean-mass hyper-responders may see dramatic LDL increases. Individual cardiovascular risk assessment needed.
—-
Connections
Entities: beta hydroxybutyrate, akkermansia muciniphila, insulin
Concepts: HDAC inhibition, mitochondrial dysfunction, SCFA production, gut brain axis, nutritional ketosis
Related interventions: mediterranean diet (alternative anti-inflammatory diet), vitamin d supplementation (synergistic immune modulation in MS)
Related pages: ketogenic diet ms (MS-specific deep dive)
Signatures: multiple sclerosis, epilepsy, pcos, parkinsons disease, autism spectrum disorder